Meta Subscription Push Could Add Billions in Recurring Revenue, Says Rosenblatt 
NIO CEO Says China’s Auto Industry Has Passed Its Golden Era Amid Weak Car Sales 
US Quantum Stocks Surge After $2 Billion Government Investment 
Samsung Union Dispute Escalates Over Semiconductor Bonus Vote 
JPMorgan Sees Biotech Sector at Turning Point, Upgrades Top Pharma Stocks 
HP Q2 2026 Earnings Beat Expectations Despite Memory Chip Pressure 
Blue Origin New Glenn Rocket Explodes During Launch Pad Test, Delaying Space Ambitions 
Synopsys Q2 FY2026 Earnings Beat Driven by AI and Semiconductor Demand 
Elon Musk Explores Possible Tesla-SpaceX Merger Amid Growing AI Investments 
Marvell Stock Rises After Record Q1 FY2027 Earnings Fueled by AI Demand 
Dell Raises 2027 Revenue Forecast as AI Server Demand Drives Record Quarterly Results 
Samsung to Invest $1.5 Billion in Vietnam Semiconductor Testing Plant by 2027 
CTOC Goes Live on Bitget Wallet Trading, Expanding Global Access to AI-Powered Healthcare Data Ecosystem 
SQM Q1 Profit More Than Doubles as Lithium Prices Surge 
DOJ Investigates Group Linked to Reid Hoffman Over E. Jean Carroll Lawsuit Funding 
Costco Q3 Fiscal 2026 Earnings Beat Expectations as Sales and E-Commerce Surge 
SpaceX IPO Could Become Largest in History with $1.8 Trillion Valuation Target 
GSK plc, a pharmaceutical industry company, has entered into an agreement that will give it exclusive rights to Johnson & Johnson’s hepatitis B therapy, known as JNJ-3989. To secure this license, the firm is paying $1 billion to J&J.
The exclusive license will give GSK the rights to further develop and commercialize J&J’s hepatitis B drug. The therapy, which is currently in development, was initially developed by Arrowhead Pharmaceuticals and licensed to J&J’s Janssen unit in 2018, as per Reuters.
Expansion of GSK’s bepirovirsen Treatment
GSK’s rights to the JNJ-3989 therapy will give a boost to the expansion of its own hepatitis B treatment called the bepirovirsen, which is already in the last phase of development. The disease reportedly affects around 300 million people worldwide. It is a life-threatening infection of the liver, and patients can develop cirrhosis and liver cancer that can lead to death.
With the agreement with Johnson & Johnson for its JNJ-3989 treatment, GSK will be able to expand and complete the development of bepirovirsen. Under the terms of the deal, the British pharma and biotech company will pay a total of $1 billion in either upfront or milestone payment arrangements to both Arrowhead and Janssen.
Arrowhead Gains New Partner for the Hepatitis B Therapy
Since Johnson &Johnson sold the rights to JNJ-3989 to GSK, the latter will eventually become the new partner of the therapy’s original developer, Arrowhead. Then again, Janssen will continue to handle the ongoing clinical trials of JNJ-3989, which is now in phase 2 testing.
“We are excited to build on promising results already demonstrated with bepirovirsen to investigate a novel sequential regimen with JNJ-3989,” GSK’s chief scientific officer, Tony Wood, said in a press release. “We believe this approach could redefine the treatment paradigm for chronic hepatitis B by helping even more patients achieve a functional cure.”
Arrowhead’s president and CEO, Chris Anzalone, Ph.D., also commented, “GSK has a global reach, a clear commitment to help those living with chronic hepatitis B, and a promising strategy for clinical studies designed to improve functional cure rates. We have great confidence in the team at GSK and look forward to seeing this program progress towards the goal of potentially helping the millions of patients with chronic hepatitis B worldwide without adequate treatment options.”
Photo by: GSK Media Library
